Robert Wesolowski

19PUBLICATIONS
160CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Mar 09, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano

|Jul 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Robert Wesolowski, Hope S Rugo, Jennifer M Specht

|Jun 12, 2025
Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis.

Dionisia Quiroga, Charles Pei, Julie A Stephens

|Sep 12, 2024
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

Olivier Rixe, John L Villano, Robert Wesolowski

|Jun 19, 2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.

Kai C C Johnson, Ai Ni, Dionisia Quiroga

|Dec 28, 2023
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.

Nicole O Williams, Dionisia Quiroga, Courtney Johnson

Pageof 4

Frequent Collaborators

7 joint publications

Bhuvaneswari Ramaswamy

7 joint publications

Anne Noonan

6 joint publications

Maryam Lustberg

6 joint publications

Daniel Stover